Cancer outcomes research—a European challenge: measures of the cancer burden

In a mission that aims to improve cancer control throughout Europe, the European Academy of Cancer Sciences has defined two key indicators of progress: within one to two decades, overall cancer‐specific 10‐year survival should reach 75%, and in each country, overall cancer mortality rates should be...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mette Kalager, Hans‐Olov Adami, Pernilla Lagergren, Karen Steindorf, Paul W. Dickman
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	cancer health‐related quality of life incidence mortality outcomes survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d06e1a18c2f64af09c21e6ffb43f7ff7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d06e1a18c2f64af09c21e6ffb43f7ff7
record_format	dspace
spelling	oai:doaj.org-article:d06e1a18c2f64af09c21e6ffb43f7ff72021-12-02T10:31:06ZCancer outcomes research—a European challenge: measures of the cancer burden1878-02611574-789110.1002/1878-0261.13012https://doaj.org/article/d06e1a18c2f64af09c21e6ffb43f7ff72021-12-01T00:00:00Zhttps://doi.org/10.1002/1878-0261.13012https://doaj.org/toc/1574-7891https://doaj.org/toc/1878-0261In a mission that aims to improve cancer control throughout Europe, the European Academy of Cancer Sciences has defined two key indicators of progress: within one to two decades, overall cancer‐specific 10‐year survival should reach 75%, and in each country, overall cancer mortality rates should be convincingly declining. To lay the ground for assessment of progress and to promote cancer outcomes research in general, we have reviewed the most common population‐based measures of the cancer burden. We emphasize the complexities and complementary approaches to measure cancer survival and the novel opportunities for improved assessment of quality of life. We propose that: incidence and mortality rates are standardized to the European population; net survival is used as the measure of prognosis but with proper adjustments for confounding when temporal trends in overall cancer survival are assessed; and cancer‐specific quality of life is measured by a combination of existing questionnaires and utilizes emerging communication technologies. We conclude that all measures are important and that a meaningful interpretation also requires a deep understanding of the larger clinical and public health context.Mette KalagerHans‐Olov AdamiPernilla LagergrenKaren SteindorfPaul W. DickmanWileyarticlecancerhealth‐related quality of lifeincidencemortalityoutcomessurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENMolecular Oncology, Vol 15, Iss 12, Pp 3225-3241 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer health‐related quality of life incidence mortality outcomes survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cancer health‐related quality of life incidence mortality outcomes survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mette Kalager Hans‐Olov Adami Pernilla Lagergren Karen Steindorf Paul W. Dickman Cancer outcomes research—a European challenge: measures of the cancer burden
description	In a mission that aims to improve cancer control throughout Europe, the European Academy of Cancer Sciences has defined two key indicators of progress: within one to two decades, overall cancer‐specific 10‐year survival should reach 75%, and in each country, overall cancer mortality rates should be convincingly declining. To lay the ground for assessment of progress and to promote cancer outcomes research in general, we have reviewed the most common population‐based measures of the cancer burden. We emphasize the complexities and complementary approaches to measure cancer survival and the novel opportunities for improved assessment of quality of life. We propose that: incidence and mortality rates are standardized to the European population; net survival is used as the measure of prognosis but with proper adjustments for confounding when temporal trends in overall cancer survival are assessed; and cancer‐specific quality of life is measured by a combination of existing questionnaires and utilizes emerging communication technologies. We conclude that all measures are important and that a meaningful interpretation also requires a deep understanding of the larger clinical and public health context.
format	article
author	Mette Kalager Hans‐Olov Adami Pernilla Lagergren Karen Steindorf Paul W. Dickman
author_facet	Mette Kalager Hans‐Olov Adami Pernilla Lagergren Karen Steindorf Paul W. Dickman
author_sort	Mette Kalager
title	Cancer outcomes research—a European challenge: measures of the cancer burden
title_short	Cancer outcomes research—a European challenge: measures of the cancer burden
title_full	Cancer outcomes research—a European challenge: measures of the cancer burden
title_fullStr	Cancer outcomes research—a European challenge: measures of the cancer burden
title_full_unstemmed	Cancer outcomes research—a European challenge: measures of the cancer burden
title_sort	cancer outcomes research—a european challenge: measures of the cancer burden
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/d06e1a18c2f64af09c21e6ffb43f7ff7
work_keys_str_mv	AT mettekalager canceroutcomesresearchaeuropeanchallengemeasuresofthecancerburden AT hansolovadami canceroutcomesresearchaeuropeanchallengemeasuresofthecancerburden AT pernillalagergren canceroutcomesresearchaeuropeanchallengemeasuresofthecancerburden AT karensteindorf canceroutcomesresearchaeuropeanchallengemeasuresofthecancerburden AT paulwdickman canceroutcomesresearchaeuropeanchallengemeasuresofthecancerburden
_version_	1718397146671087616

Cancer outcomes research—a European challenge: measures of the cancer burden

Ejemplares similares